List of Excipients in Branded Drug DEXRAZOXANE

« Back to Dashboard

Generic Drugs Containing DEXRAZOXANE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dexrazoxane	0143-9247	HYDROCHLORIC ACID
Alvogen Inc	dexrazoxane for injection	47781-578	HYDROCHLORIC ACID
Breckenridge Pharmaceutical Inc	dexrazoxane hydrochloride	51991-942	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in DEXRAZOXANE?

# Of NDCs	Excipient
8	HYDROCHLORIC ACID

Dexrazoxane Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Dexrazoxane is an injectable anthracycline-protection drug with a relatively simple excipient profile but meaningful formulation constraints. Commercial value is concentrated in sterile manufacturing, rapid reconstitution, container-closure performance, supply reliability, and hospital workflow rather than in conventional oral formulation innovation. The strongest opportunities are ready-to-use or faster-preparation presentations, differentiated vial configurations, global supply, and contract manufacturing.

What is dexrazoxane and how is it administered?

Dexrazoxane is an intracellular iron-chelating agent used in two principal settings:

1. Prevention of anthracycline-associated cardiomyopathy in selected oncology patients.
2. Treatment of anthracycline extravasation, particularly doxorubicin or other anthracycline leakage into surrounding tissue.

The drug is administered intravenously after reconstitution. Commercial products have generally been supplied as sterile lyophilized powder in single-dose vials. The injectable product is dexrazoxane hydrochloride, with the labeled quantity commonly expressed as dexrazoxane equivalent.

The clinical presentation differs by indication. Extravasation treatment requires rapid preparation and administration, while cardioprotection is administered in a scheduled oncology regimen. This distinction creates different commercial priorities:

Commercial attribute	Extravasation use	Cardioprotection use
Treatment timing	Emergency or urgent	Scheduled before anthracycline dosing
Main buyer concern	Immediate availability	Reimbursement, protocol adoption, supply
Formulation priority	Fast reconstitution and low preparation burden	Dose flexibility and predictable supply
Typical setting	Hospital pharmacy, emergency oncology care	Infusion center and hospital oncology unit
Competitive risk	Product availability and operational convenience	Clinical protocol and purchasing economics
Differentiation potential	Ready-to-use or rapid-mix product	Lower-cost vial sizes and global registration

The drug is not a biologic. Biosimilar rules do not apply. Any follow-on product would generally proceed through an abbreviated or full small-molecule pathway, depending on jurisdiction and product attributes.

What excipients are used in dexrazoxane injection?

The marketed powder-for-injection approach uses a minimal excipient strategy. U.S. labeling for Totect identifies dexrazoxane hydrochloride as the active ingredient and does not establish a broad excipient system comparable to that used in complex liquid injectables (U.S. Food and Drug Administration [FDA], 2007).

Typical product components include:

Component	Function
Dexrazoxane hydrochloride	Active pharmaceutical ingredient
Sterile Water for Injection	Initial reconstitution diluent
Sodium chloride injection or compatible infusion fluid	Further dilution, depending on product instructions
Glass vial and elastomeric closure	Sterile containment and stability protection

The central formulation advantage is the absence of a complex buffer, surfactant, preservative, or co-solvent system in the freeze-dried cake. That reduces excipient-related toxicology, compatibility, and regulatory burden. It also shifts development risk toward the lyophilization cycle, reconstitution time, solution stability, particulate control, and container-closure integrity.

The exact excipient disclosure must be assessed product by product. European products, U.S. products, and hospital-compounded presentations may have different diluent instructions and packaging configurations. Excipients in the reconstitution or infusion solution should not be treated as ingredients in the finished lyophilized cake.

Why is a lyophilized dexrazoxane formulation commercially attractive?

A lyophilized presentation offers several advantages for a molecule administered in acute oncology settings:

• Better solid-state stability than a ready-to-use aqueous solution.
• Lower risk of hydrolysis and concentration drift during shelf life.
• Reduced need for antimicrobial preservatives.
• Compatibility with single-dose hospital use.
• More practical global cold-chain and distribution requirements.
• Lower risk of microbial growth before administration.

The commercial disadvantage is preparation time. The healthcare provider must reconstitute the vial, inspect the solution, and transfer it into an infusion container. That process creates opportunities for a competing product with improved workflow.

A reformulated product would need to demonstrate that the benefit is clinically or operationally meaningful. A modest reduction in reconstitution time may not justify a higher acquisition price unless it improves emergency availability, reduces pharmacy labor, limits medication errors, or supports use in smaller hospitals.

What formulation patents could protect a dexrazoxane product?

The active ingredient itself is an older compound, and commercial protection is unlikely to depend on a new composition-of-matter patent. Potentially protectable subject matter includes:

• A stable aqueous dexrazoxane solution.
• A specific pH range that improves stability.
• A defined concentration range for an infusion-ready product.
• A novel buffer or tonicity system.
• A lyophilized cake with improved reconstitution time.
• A low-particulate formulation.
• A container-closure system that limits adsorption or extractables.
• A ready-to-use bag or syringe presentation.
• A formulation with an extended in-use period.
• A manufacturing process that improves yield or controls polymorphism.
• A specific dosing or administration method.

The most commercially relevant claim categories are likely formulation and manufacturing claims rather than broad active-ingredient claims. A formulation patent must withstand obviousness scrutiny because dexrazoxane already has an established injectable route, known reconstitution practices, and extensive oncology use.

A robust patent program would combine composition claims with process claims. The composition claims could cover concentration, pH, buffer, stabilizer, and solvent. The process claims could cover lyophilization parameters, filling conditions, reconstitution sequence, and storage. Container-closure claims may provide a practical layer of protection but are often easier to design around.

How strong is the dexrazoxane patent estate?

The commercial patent estate appears weaker than the regulatory and manufacturing barriers. Dexrazoxane has been used clinically for decades, and the principal products are established injectable presentations. The likely competitive barriers are:

1. Sterile manufacturing capability.
2. Demonstration of pharmaceutical equivalence.
3. Hospital formulary access.
4. Reliable supply of a low-volume oncology product.
5. Global regulatory registrations.
6. Technical validation of reconstitution and stability.
7. Quality-system and pharmacovigilance obligations.

The opportunity for new intellectual property is higher in delivery and manufacturing than in the base molecule. A company seeking exclusivity should avoid relying on a narrow excipient substitution alone. The strongest strategy would connect a formulation change to a measurable product benefit, such as faster administration, extended stability, reduced preparation steps, or improved compatibility with automated compounding systems.

What is the FDA regulatory status of dexrazoxane products?

The FDA has approved dexrazoxane products for different clinical purposes. Totect received U.S. approval for anthracycline extravasation, while dexrazoxane has also been marketed historically under the Zinecard name for cardioprotection in selected breast-cancer treatment settings (FDA, 2007; FDA, 1995).

Regulatory analysis must separate:

• Indication.
• Strength.
• Dosage form.
• Reference product.
• Labeling.
• Pediatric status.
• Reconstitution instructions.
• Supplier and manufacturing site.

A product approved for extravasation is not automatically interchangeable for every cardioprotection protocol. The approved indication, dosing instructions, and reference listing determine the commercial pathway.

The product is a small-molecule injectable rather than a biologic. The principal regulatory work for a follow-on product is expected to involve chemistry, manufacturing and controls, sterility assurance, container closure, comparative composition, stability, and clinical labeling rather than biosimilar analytical comparability.

What is the Orange Book status of dexrazoxane?

The Orange Book analysis should be conducted at the product and NDA level. Listed patents, exclusivity, and therapeutic-equivalence evaluations can change as products are approved, transferred, discontinued, or delisted. The controlling source is the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database and the applicable NDA labeling.

For commercial diligence, the relevant questions are:

• Is the target product listed as a reference listed drug?
• Are any patents or regulatory exclusivities currently listed?
• Is a generic applicant eligible to file an ANDA?
• Does the proposed product match the reference product’s strength and dosage form?
• Are the intended indications protected by method-of-use listings?
• Does a Paragraph IV certification create litigation exposure?

An applicant should not assume that an absence of an active patent listing eliminates all launch risk. Litigation can arise from patents not listed in the Orange Book, including manufacturing, formulation, or contractual disputes. Conversely, an old method-of-use patent may have little practical value if the product can launch for a non-covered indication.

When does dexrazoxane lose exclusivity?

Dexrazoxane’s original compound and early product exclusivity periods are historical rather than upcoming exclusivity events. The commercial question is therefore generic competition, not the loss of a near-term new-drug exclusivity period.

For a new dexrazoxane product, exclusivity could arise from:

Protection type	Potential commercial effect
New formulation patent	Delays or complicates formulation copying
New indication patent	Limits use for a protected clinical purpose
Orphan-drug exclusivity, if applicable	May restrict approval of the same drug for the same rare indication
Pediatric exclusivity	Adds six months to qualifying exclusivity
New clinical investigation exclusivity	May protect certain new indications
Manufacturing patent	Raises the cost of direct process replication
Trade secret	Protects know-how without public disclosure

The value of regulatory exclusivity depends on the precise indication and approval basis. It should not be inferred solely from the age of the active ingredient.

What Paragraph IV challenges and litigation affect dexrazoxane?

A Paragraph IV challenge would be relevant if a generic applicant certifies that a listed patent is invalid, unenforceable, or not infringed. The practical litigation risk depends on whether any active Orange Book-listed patents cover the reference product, its use, or its formulation.

The key diligence points are:

• Current Orange Book patent listings.
• ANDA filing date and certification type.
• Notice-letter timing.
• District-court filing within the statutory period.
• Potential 30-month stay.
• Preliminary injunction risk.
• Settlement restrictions.
• Authorized-generic arrangements.
• Whether the challenger has a non-infringing label.

No broad biosimilar litigation framework applies because dexrazoxane is not a biologic. A generic entrant would face the economics of injectable drug development, not the interchangeability and patent dance issues associated with monoclonal antibodies.

What excipient strategies create the best commercial opportunities?

Ready-to-use aqueous dexrazoxane

A ready-to-use bag, vial, or syringe could reduce pharmacy preparation. The technical challenge is aqueous stability over the intended shelf life. Development would likely require control of pH, oxygen exposure, metal ions, concentration, light, and container interaction.

Potential value drivers include:

• Faster emergency administration.
• Lower manipulation risk.
• Reduced pharmacy labor.
• Less waste from reconstitution.
• Better suitability for automated dispensing.
• Simplified use in smaller oncology centers.

The principal risk is that a stable liquid may require a more complex excipient system or specialized packaging.

Faster-reconstituting lyophilized product

A lyophilized product with a controlled cake structure may offer a lower-risk commercial path than a liquid. Optimization targets include cake porosity, residual moisture, reconstitution volume, agitation requirements, and time to a clear solution.

This approach can preserve the stability advantages of a powder while improving workflow. A patent position could cover the formulation and lyophilization cycle if the performance improvement is reproducible.

Alternative vial sizes

Dose requirements may vary by patient weight, indication, and protocol. A 500 mg single-dose vial can create waste when the calculated dose is lower than the vial content. Smaller or multi-size presentations could improve dose efficiency, although they increase manufacturing complexity and inventory burden.

Vial-size differentiation is often more commercially practical than a major reformulation. It can also support tenders and hospital purchasing programs.

Infusion-compatible presentations

A product designed for direct dilution into a standard infusion container could reduce transfer steps. The formulation must maintain chemical and physical stability in the selected diluent, infusion bag, and administration set.

The opportunity is strongest where pharmacy compounding labor is expensive or where emergency treatment protocols require rapid release from pharmacy.

Global presentation and supply strategy

Dexrazoxane has a specialized oncology market. A supplier with registrations in the United States, European Union, United Kingdom, Canada, Japan, and selected emerging markets could obtain value from geographic breadth rather than high unit volume.

Manufacturing redundancy is commercially important. A single-site sterile injectable supply chain creates procurement risk and can support premium pricing if the supplier maintains dependable availability.

How does dexrazoxane compare with competing cardioprotective strategies?

Dexrazoxane competes with clinical alternatives rather than with a direct pharmacologic substitute in every use case. For anthracycline cardioprotection, clinicians may use dose limitation, liposomal anthracycline formulations, cardiac monitoring, or alternative chemotherapy regimens. None is a direct substitute for extravasation treatment, where local management, aspiration, cooling or warming protocols, and other interventions may be used according to the offending anthracycline and institutional policy.

Strategy	Primary use	Formulation opportunity
Dexrazoxane	Cardioprotection and selected extravasation treatment	Faster preparation, stable liquid, vial optimization
Liposomal doxorubicin	Altered anthracycline delivery	Less direct competition in extravasation treatment
Cardiac monitoring and dose management	Risk mitigation	No comparable excipient opportunity
Local extravasation protocols	Acute tissue injury management	Competes mainly in treatment algorithms
Alternative chemotherapy	Disease-management substitution	Reduces demand in selected regimens

The commercial opportunity is therefore highly indication-specific. A product optimized for extravasation should emphasize immediate access and preparation speed. A cardioprotection product should emphasize protocol inclusion, reimbursement, and predictable supply.

What manufacturing and IP barriers affect new dexrazoxane products?

Dexrazoxane is chemically simpler than many oncology injectables, but sterile production remains a substantial barrier. Critical development areas include:

• API impurity and residual-solvent control.
• Sterile filtration or aseptic processing strategy.
• Lyophilization cycle development.
• Particulate and visible-inspection performance.
• Reconstitution time.
• Solution clarity and color.
• In-use stability.
• Container-closure integrity.
• Extractables and leachables.
• Shipping and temperature excursion studies.
• Compatibility with infusion materials.
• Batch-scale reproducibility.

A contract development and manufacturing organization with sterile lyophilization capacity may create a faster route to market than building a dedicated facility. The commercial tradeoff is reliance on third-party capacity and exposure to contract-manufacturing minimums.

The best defensible know-how may involve cycle design, scale-up, primary packaging, and stability control rather than a novel excipient. Trade secrets can complement formulation patents, especially for process parameters that are difficult to reverse engineer.

What is the revenue exposure and market opportunity for dexrazoxane?

Public market data for dexrazoxane are limited because sales are distributed among branded products, generic injectables, hospital tenders, and regional distributors. The market is likely niche by patient volume but strategically important because the product is used in high-acuity oncology care.

Revenue depends on:

• Anthracycline treatment volume.
• Use of cardioprotection protocols.
• Extravasation incidence.
• Hospital stocking practices.
• Product availability.
• Reimbursement.
• Vial waste.
• Generic price competition.
• Geographic registration.
• Supply contracts.

A premium formulation can support higher pricing only if it reduces total treatment cost or improves clinical workflow. The strongest value proposition is likely a measurable reduction in preparation time and waste, not a higher active concentration alone.

Key Takeaways

• Dexrazoxane is primarily an injectable sterile-powder opportunity, not an oral excipient-development opportunity.
• The marketed formulation approach uses a minimal excipient system centered on lyophilized dexrazoxane hydrochloride.
• The highest-value formulation opportunities are ready-to-use liquid products, faster-reconstituting lyophilized cakes, infusion-compatible presentations, and optimized vial sizes.
• Patent value is likely to come from formulation, manufacturing, container closure, and administration claims rather than the old active ingredient.
• Dexrazoxane is a small molecule, so biosimilar rules do not apply.
• Orange Book, Paragraph IV, and settlement analysis must be performed at the specific NDA, reference product, patent-listing, and indication level.
• Sterile manufacturing capability, reliable supply, and hospital procurement access may be stronger barriers than the base patent estate.
• A differentiated product must demonstrate operational value through faster preparation, reduced waste, improved stability, or broader geographic availability.

FAQs

Is dexrazoxane a biologic or a generic drug?

Dexrazoxane is a synthetic small molecule. A follow-on product would generally be evaluated through a generic or conventional small-molecule regulatory pathway, not the biosimilar pathway.

Can dexrazoxane be formulated as a prefilled syringe?

Potentially, but the feasibility depends on aqueous stability, concentration, syringe-material compatibility, particulate control, and shelf-life performance. A prefilled syringe would require a stronger stability package than a conventional lyophilized vial.

Which excipient is most important in a dexrazoxane liquid formulation?

The critical excipient system would likely involve pH control and stabilization against degradation rather than a conventional preservative. The final selection would depend on forced-degradation, container-closure, and infusion-compatibility results.

Is a dexrazoxane ready-to-use product likely to receive formulation-patent protection?

It may receive patent protection if the formulation has a novel and non-obvious combination of concentration, pH, stabilizer, solvent, packaging, or stability performance. A simple liquid conversion without an unexpected technical benefit would face greater validity risk.

What is the most practical commercial entry strategy for dexrazoxane?

The most practical strategy is often a sterile generic or differentiated lyophilized product supported by reliable supply, competitive vial economics, and a faster or simpler reconstitution process. A ready-to-use product offers greater differentiation but also carries higher stability and packaging-development risk.

References

1. European Medicines Agency. (2011). Cardioxane: EPAR product information. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (1995). Zinecard (dexrazoxane hydrochloride) prescribing information. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2007). Totect (dexrazoxane hydrochloride) prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/

5. National Center for Biotechnology Information. (2024). PubChem compound summary: Dexrazoxane. PubChem. https://pubchem.ncbi.nlm.nih.gov/